{"id":"amrubicin","rwe":[],"tags":[{"label":"amrubicin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"L01DB10","category":"atc"},{"label":"Active","category":"status"},{"label":"Antineoplastic Agents","category":"pharmacology"}],"phase":"phase_3","safety":{"safetySignals":[{"llr":128.859,"date":"","count":30,"signal":"Disease recurrence","source":"DrugCentral FAERS","actionTaken":"Reported 30 times (LLR=129)"}],"commonSideEffects":[{"effect":"Anaemia","drugRate":"63.5%","organSystem":"Blood and lymphatic system disorders","placeboRate":"","totalAtRisk":244,"totalAffected":155,"trialsReporting":1},{"effect":"Nausea","drugRate":"31.6%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":244,"totalAffected":77,"trialsReporting":1},{"effect":"Neutropenia","drugRate":"29.9%","organSystem":"Blood and lymphatic system disorders","placeboRate":"","totalAtRisk":244,"totalAffected":73,"trialsReporting":1},{"effect":"Fatigue","drugRate":"29.9%","organSystem":"General disorders","placeboRate":"","totalAtRisk":244,"totalAffected":73,"trialsReporting":1},{"effect":"Thrombocytopenia","drugRate":"24.6%","organSystem":"Blood and lymphatic system disorders","placeboRate":"","totalAtRisk":244,"totalAffected":60,"trialsReporting":1},{"effect":"Leukopenia","drugRate":"22.1%","organSystem":"Blood and lymphatic system disorders","placeboRate":"","totalAtRisk":244,"totalAffected":54,"trialsReporting":1},{"effect":"Constipation","drugRate":"22.1%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":244,"totalAffected":54,"trialsReporting":1},{"effect":"Decreased appetite","drugRate":"22.1%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":244,"totalAffected":54,"trialsReporting":1},{"effect":"Platelet count decreased","drugRate":"16.8%","organSystem":"Investigations","placeboRate":"","totalAtRisk":244,"totalAffected":41,"trialsReporting":1},{"effect":"Neutrophil count decreased","drugRate":"16.4%","organSystem":"Investigations","placeboRate":"","totalAtRisk":244,"totalAffected":40,"trialsReporting":1},{"effect":"Diarrhoea","drugRate":"14.3%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":244,"totalAffected":35,"trialsReporting":1},{"effect":"Asthenia","drugRate":"14.3%","organSystem":"General disorders","placeboRate":"","totalAtRisk":244,"totalAffected":35,"trialsReporting":1},{"effect":"Cough","drugRate":"13.9%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":244,"totalAffected":34,"trialsReporting":1},{"effect":"White blood cell count decreased","drugRate":"13.1%","organSystem":"Investigations","placeboRate":"","totalAtRisk":244,"totalAffected":32,"trialsReporting":1},{"effect":"Vomiting","drugRate":"11.5%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":244,"totalAffected":28,"trialsReporting":1},{"effect":"Pyrexia","drugRate":"11.1%","organSystem":"General disorders","placeboRate":"","totalAtRisk":244,"totalAffected":27,"trialsReporting":1},{"effect":"Dyspnoea","drugRate":"11.1%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":244,"totalAffected":27,"trialsReporting":1},{"effect":"Dizziness","drugRate":"10.2%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":244,"totalAffected":25,"trialsReporting":1},{"effect":"Hyponatraemia","drugRate":"9.4%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":244,"totalAffected":23,"trialsReporting":1},{"effect":"Headache","drugRate":"8.6%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":244,"totalAffected":21,"trialsReporting":1},{"effect":"Insomnia","drugRate":"8.6%","organSystem":"Psychiatric disorders","placeboRate":"","totalAtRisk":244,"totalAffected":21,"trialsReporting":1},{"effect":"Hypokalaemia","drugRate":"7.8%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":244,"totalAffected":19,"trialsReporting":1},{"effect":"Alopecia","drugRate":"7.8%","organSystem":"Skin and subcutaneous tissue disorders","placeboRate":"","totalAtRisk":244,"totalAffected":19,"trialsReporting":1},{"effect":"Arthralgia","drugRate":"7.0%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":244,"totalAffected":17,"trialsReporting":1},{"effect":"Weight decreased","drugRate":"6.6%","organSystem":"Investigations","placeboRate":"","totalAtRisk":244,"totalAffected":16,"trialsReporting":1},{"effect":"Pneumonia","drugRate":"6.1%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":244,"totalAffected":15,"trialsReporting":1},{"effect":"Back pain","drugRate":"6.1%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":244,"totalAffected":15,"trialsReporting":1},{"effect":"Productive cough","drugRate":"6.1%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":244,"totalAffected":15,"trialsReporting":1},{"effect":"Alanine aminotransferase increased","drugRate":"5.7%","organSystem":"Investigations","placeboRate":"","totalAtRisk":244,"totalAffected":14,"trialsReporting":1},{"effect":"Hypoalbuminaemia","drugRate":"5.7%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":244,"totalAffected":14,"trialsReporting":1},{"effect":"Chest pain","drugRate":"4.9%","organSystem":"General disorders","placeboRate":"","totalAtRisk":244,"totalAffected":12,"trialsReporting":1},{"effect":"Lymphocyte count decreased","drugRate":"4.9%","organSystem":"Investigations","placeboRate":"","totalAtRisk":244,"totalAffected":12,"trialsReporting":1},{"effect":"Rash","drugRate":"4.9%","organSystem":"Skin and subcutaneous tissue disorders","placeboRate":"","totalAtRisk":244,"totalAffected":12,"trialsReporting":1},{"effect":"Lymphopenia","drugRate":"4.1%","organSystem":"Blood and lymphatic system disorders","placeboRate":"","totalAtRisk":244,"totalAffected":10,"trialsReporting":1},{"effect":"Abdominal pain","drugRate":"4.1%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":244,"totalAffected":10,"trialsReporting":1},{"effect":"Pruritus","drugRate":"3.7%","organSystem":"Skin and subcutaneous tissue disorders","placeboRate":"","totalAtRisk":244,"totalAffected":9,"trialsReporting":1},{"effect":"Urinary tract infection","drugRate":"3.3%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":244,"totalAffected":8,"trialsReporting":1},{"effect":"Aspartate aminotransferase increased","drugRate":"3.3%","organSystem":"Investigations","placeboRate":"","totalAtRisk":244,"totalAffected":8,"trialsReporting":1},{"effect":"Hypomagnesaemia","drugRate":"3.3%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":244,"totalAffected":8,"trialsReporting":1},{"effect":"Myalgia","drugRate":"2.5%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":244,"totalAffected":6,"trialsReporting":1},{"effect":"Dysgeusia","drugRate":"1.6%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":244,"totalAffected":4,"trialsReporting":1},{"effect":"Hypertension","drugRate":"1.6%","organSystem":"Vascular disorders","placeboRate":"","totalAtRisk":244,"totalAffected":4,"trialsReporting":1},{"effect":"Dyspepsia","drugRate":"0.8%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":244,"totalAffected":2,"trialsReporting":1},{"effect":"Cytokine release syndrome","drugRate":"0.8%","organSystem":"Immune system disorders","placeboRate":"","totalAtRisk":244,"totalAffected":2,"trialsReporting":1}],"seriousAdverseEvents":[{"event":"Febrile neutropenia","detail":"Blood and lymphatic system disorders. 1 trial(s).","severity":"serious","incidence":"9.8%"},{"event":"Pneumonia","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"8.6%"},{"event":"Thrombocytopenia","detail":"Blood and lymphatic system disorders. 1 trial(s).","severity":"serious","incidence":"4.5%"},{"event":"Anaemia","detail":"Blood and lymphatic system disorders. 1 trial(s).","severity":"serious","incidence":"4.1%"},{"event":"Neutropenia","detail":"Blood and lymphatic system disorders. 1 trial(s).","severity":"serious","incidence":"2.5%"},{"event":"Platelet count decreased","detail":"Investigations. 1 trial(s).","severity":"serious","incidence":"2.5%"},{"event":"Pancytopenia","detail":"Blood and lymphatic system disorders. 1 trial(s).","severity":"serious","incidence":"2.0%"},{"event":"Hyponatraemia","detail":"Metabolism and nutrition disorders. 1 trial(s).","severity":"serious","incidence":"1.6%"},{"event":"Superior vena cava syndrome","detail":"Vascular disorders. 1 trial(s).","severity":"serious","incidence":"1.6%"},{"event":"Cardiac arrest","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"1.2%"},{"event":"Bacterial infection","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"1.2%"},{"event":"Neutrophil count decreased","detail":"Investigations. 1 trial(s).","severity":"serious","incidence":"1.2%"},{"event":"Back pain","detail":"Musculoskeletal and connective tissue disorders. 1 trial(s).","severity":"serious","incidence":"1.2%"},{"event":"Seizure","detail":"Nervous system disorders. 1 trial(s).","severity":"serious","incidence":"1.2%"},{"event":"Respiratory failure","detail":"Respiratory, thoracic and mediastinal disorders. 1 trial(s).","severity":"serious","incidence":"1.2%"},{"event":"Leukopenia","detail":"Blood and lymphatic system disorders. 1 trial(s).","severity":"serious","incidence":"0.8%"},{"event":"Diarrhoea","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.8%"},{"event":"Cholangitis","detail":"Hepatobiliary disorders. 1 trial(s).","severity":"serious","incidence":"0.8%"},{"event":"Pneumonia aspiration","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.8%"},{"event":"Respiratory tract infection","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.8%"},{"event":"Sepsis","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.8%"},{"event":"Upper respiratory tract infection","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.8%"},{"event":"Bone pain","detail":"Musculoskeletal and connective tissue disorders. 1 trial(s).","severity":"serious","incidence":"0.8%"},{"event":"Dyspnoea","detail":"Respiratory, thoracic and mediastinal disorders. 1 trial(s).","severity":"serious","incidence":"0.8%"},{"event":"Pleural effusion","detail":"Respiratory, thoracic and mediastinal disorders. 1 trial(s).","severity":"serious","incidence":"0.8%"},{"event":"Pneumonitis","detail":"Respiratory, thoracic and mediastinal disorders. 1 trial(s).","severity":"serious","incidence":"0.8%"},{"event":"Cardiac failure","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.4%"},{"event":"Cardiac tamponade","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.4%"},{"event":"Cardio-respiratory arrest","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.4%"},{"event":"Pericardial effusion","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.4%"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T08:41:13.157895+00:00"}},"allNames":["SM-5887","amrubicin hydrochloride","amrubicin HCl","amrubicin"],"offLabel":[],"synonyms":["SM-5887","amrubicin hydrochloride","amrubicin HCl","amrubicin"],"timeline":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"amrubicin","explanation":"Imagine your DNA as a long, twisted ladder. Amrubicin gets in between the rungs of the ladder, making it hard for the cell to fix any mistakes in the DNA. This ultimately leads to the cell dying, which is what we want when treating cancer.","oneSentence":"Amrubicin works by inserting itself between DNA strands, disrupting the cell's ability to repair DNA damage and leading to cell death.","technicalDetail":"Amrubicin intercalates DNA by binding to the minor groove, thereby inhibiting the activity of topoisomerase II and inducing DNA strand breaks, which triggers apoptosis in cancer cells."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/202","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=AMRUBICIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMRUBICIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:47:06.951849","_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T08:41:22.150984+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"doxorubicin","drugSlug":"doxorubicin","fdaApproval":"1974-08-07","genericCount":24,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"daunorubicin","drugSlug":"daunorubicin","fdaApproval":"1979-12-19","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"epirubicin","drugSlug":"epirubicin","fdaApproval":"1999-09-15","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"idarubicin","drugSlug":"idarubicin","fdaApproval":"1990-09-27","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"mitoxantrone","drugSlug":"mitoxantrone","fdaApproval":"1987-12-23","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"valrubicin","drugSlug":"valrubicin","fdaApproval":"1998-09-25","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"amrubicin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"doxorubicin","brandName":"doxorubicin","genericName":"doxorubicin","approvalYear":"1974","relationship":"same-class"},{"drugId":"daunorubicin","brandName":"daunorubicin","genericName":"daunorubicin","approvalYear":"1979","relationship":"same-class"},{"drugId":"epirubicin","brandName":"epirubicin","genericName":"epirubicin","approvalYear":"1999","relationship":"same-class"},{"drugId":"idarubicin","brandName":"idarubicin","genericName":"idarubicin","approvalYear":"1990","relationship":"same-class"},{"drugId":"mitoxantrone","brandName":"mitoxantrone","genericName":"mitoxantrone","approvalYear":"1987","relationship":"same-class"},{"drugId":"valrubicin","brandName":"valrubicin","genericName":"valrubicin","approvalYear":"1998","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06801834","phase":"PHASE3","title":"Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2025-04-04","conditions":["Extensive Stage Small Cell Lung Cancer (ES-SCLC)"],"enrollment":695,"completionDate":"2029-10"},{"nctId":"NCT07218146","phase":"PHASE3","title":"A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)","status":"RECRUITING","sponsor":"Zai Lab (Shanghai) Co., Ltd.","startDate":"2025-11-30","conditions":["Small-cell Lung Cancer"],"enrollment":480,"completionDate":"2028-11-30"},{"nctId":"NCT06203210","phase":"PHASE3","title":"A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-05-21","conditions":["Small Cell Lung Cancer"],"enrollment":540,"completionDate":"2029-02-22"},{"nctId":"NCT07365241","phase":"PHASE3","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"AbbVie","startDate":"2026-04-14","conditions":["Small Cell Lung Cancer"],"enrollment":531,"completionDate":"2030-09"},{"nctId":"NCT05740566","phase":"PHASE3","title":"Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2023-05-31","conditions":["Small Cell Lung Cancer (SCLC)"],"enrollment":509,"completionDate":"2028-03-26"},{"nctId":"NCT01904253","phase":"PHASE2","title":"A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy","status":"TERMINATED","sponsor":"Taiho Oncology, Inc.","startDate":"2013-07","conditions":["Small Cell Lung Cancer (SCLC)"],"enrollment":18,"completionDate":"2014-06"},{"nctId":"NCT02481830","phase":"PHASE3","title":"Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-09-14","conditions":["Lung Cancer"],"enrollment":569,"completionDate":"2022-08-30"},{"nctId":"NCT01033032","phase":"PHASE1,PHASE2","title":"Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2009-12","conditions":["Metastatic Breast Cancer"],"enrollment":78,"completionDate":"2014-10"},{"nctId":"NCT00286169","phase":"PHASE3","title":"Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)","status":"TERMINATED","sponsor":"Sumitomo Pharma Co., Ltd.","startDate":"2006-04","conditions":["Small-cell Lung Cancer"],"enrollment":130,"completionDate":""},{"nctId":"NCT01207011","phase":"PHASE3","title":"Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma Co., Ltd.","startDate":"2010-10","conditions":["Lung Cancer"],"enrollment":202,"completionDate":"2014-06"},{"nctId":"NCT03253068","phase":"PHASE2","title":"Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer","status":"UNKNOWN","sponsor":"Wakayama Medical University","startDate":"2017-08-01","conditions":["Small Cell Lung Cancer Extensive Stage"],"enrollment":25,"completionDate":"2020-12-31"},{"nctId":"NCT00388960","phase":"PHASE2","title":"Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Celgene","startDate":"2006-11-01","conditions":["Small Cell Lung Cancer"],"enrollment":99,"completionDate":"2010-12-01"},{"nctId":"NCT00547651","phase":"PHASE3","title":"AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy","status":"COMPLETED","sponsor":"Celgene","startDate":"2007-09-01","conditions":["Small Cell Lung Cancer"],"enrollment":637,"completionDate":"2011-05-01"},{"nctId":"NCT00915083","phase":"PHASE1","title":"A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.","status":"COMPLETED","sponsor":"Celgene","startDate":"2009-06-01","conditions":["Advanced Solid Tumors"],"enrollment":24,"completionDate":"2011-05-01"},{"nctId":"NCT00375193","phase":"PHASE2","title":"Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy","status":"COMPLETED","sponsor":"Celgene","startDate":"2006-11-01","conditions":["Small Cell Lung Cancer"],"enrollment":75,"completionDate":"2009-03-01"},{"nctId":"NCT01364727","phase":"PHASE2","title":"A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies","status":"COMPLETED","sponsor":"Heather Wakelee","startDate":"2011-06","conditions":["Thymoma","Thymus Cancer","Thymic Carcinoma"],"enrollment":33,"completionDate":"2018-12-31"},{"nctId":"NCT01355705","phase":"PHASE1,PHASE2","title":"Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Michaela Liedtke","startDate":"2011-08","conditions":["Multiple Myeloma"],"enrollment":14,"completionDate":"2017-07"},{"nctId":"NCT01331824","phase":"PHASE2","title":"Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma","status":"TERMINATED","sponsor":"Matthew Galsky","startDate":"2011-02","conditions":["Bladder Cancer"],"enrollment":22,"completionDate":"2015-07"},{"nctId":"NCT01259375","phase":"PHASE2","title":"Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"University of Utah","startDate":"2011-09","conditions":["Soft Tissue Sarcoma"],"enrollment":24,"completionDate":"2016-02"},{"nctId":"NCT01076504","phase":"PHASE2","title":"A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2009-12","conditions":["Extensive-Stage Small Cell Lung Cancer"],"enrollment":81,"completionDate":"2015-03"},{"nctId":"NCT00890955","phase":"PHASE1","title":"Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies","status":"COMPLETED","sponsor":"Lawrence Einhorn","startDate":"2009-03","conditions":["Lung Cancer"],"enrollment":36,"completionDate":"2010-07"},{"nctId":"NCT00660504","phase":"PHASE3","title":"Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2008-04","conditions":["Lung Cancer"],"enrollment":300,"completionDate":"2012-08"},{"nctId":"NCT00132054","phase":"PHASE1","title":"Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Japan Multinational Trial Organization","startDate":"2004-05","conditions":["Lung Cancer"],"enrollment":30,"completionDate":"2008-11"},{"nctId":"NCT00319969","phase":"PHASE2","title":"Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.","status":"COMPLETED","sponsor":"Celgene Corporation","startDate":"2006-04","conditions":["Small Cell Lung Cancer"],"enrollment":76,"completionDate":"2009-01"},{"nctId":"NCT00380835","phase":"PHASE2","title":"Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"Celgene Corporation","startDate":"","conditions":["Metastatic Breast Cancer"],"enrollment":66,"completionDate":"2007-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"93N13LB4Z2","CHEBI":"CHEBI:135779","INN_ID":"6802","UMLSCUI":"C0762659","ChEMBL_ID":"CHEMBL1186894","KEGG_DRUG":"D08854","DRUGBANK_ID":"DB06263","PUBCHEM_CID":"3035016","SECONDARY_CAS_RN":"110311-30-3","MESH_SUPPLEMENTAL_RECORD_UI":"C055866"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":349,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01DB10","allCodes":["L01DB10"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"structuredTrialResults":[{"hr":"0.599","nctId":"NCT05740566","phase":"PHASE3","pValue":"<0.001","ciLower":"0.468","ciUpper":"0.768","endpoint":"Overall Survival (OS)","enrollment":509}],"genericManufacturerList":[],"status":"active","brandName":"AMRUBICIN","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amrubicin is a small molecule that inhibits DNA topoisomerase 2-alpha, a type of enzyme involved in DNA replication. It has been studied in clinical trials for various conditions, including metastatic breast cancer, thymoma, thymus cancer, thymic carcinoma, and small cell lung cancer.","enrichmentLevel":5,"visitCount":1,"trialStats":{"total":2,"withResults":1},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T08:41:22.150984+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}